10x Genomics, Inc. — Director's Dealing 2019

Sep 12, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2019-09-11

Reporting Person: CRUTCHFIELD BRADFORD (Chief Commercial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.16	2027-02-03	Class B Common Stock (800000)		Direct
Stock Option (right to buy)	$1.20	2027-10-18	Class B Common Stock (25000)		Direct
Stock Option (right to buy)	$5.04	2028-11-02	Class B Common Stock (125000)		Direct
Stock Option (right to buy)	$11.48	2029-05-10	Class B Common Stock (70000)		Direct

Footnotes

F1: One-fourth of the shares subject to the option vested on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares.

F2: Each share of Class B Common Stock shall be reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock.

F3: One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F4: One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F5: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.